7 completed, 6 terminated, 3 recruiting, 1 active not recruiting. 10 Phase 2, 7 Phase 1, 2 Phase 3, 1 Phase 4.
Follow Lymphoma, Small Lymphocytic: new trials by email Literature Review of Lymphoma, Small Lymphocytic trials Research Report on Lymphoma, Small Lymphocytic
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Pirtobrutinib, Idelalisib - Chronic Lymphocytic Leukemia, Lymphoma, Small Lymphocytic | Phase 4 | Recruiting | Eli Lilly and Company | 150 | 2026-03-09 | 2026-09-22 |
| A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010). Nemtabrutinib, Venetoclax, Rituximab - Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Chronic Lymphocytic | Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 735 | 2023-08-08 | 2026-10-15 |
| Intermittent Fasting and CLL/SLL Intermittent fast - Neoplasms, Leukemia, Lymphocytic, Chronic | Phase 1 | Completed | Eleah Stringer | 15 | 2021-02-03 | 2023-02-14 |
| Observational Trial of Real-World Treatment Utilization and Effectiveness of PI3K-inhibitors in CLL/SLL and FL duvelisib, PI3K inhibitor - Lymphoma, Small Lymphocytic, Lymphoma | Terminated | SecuraBio | 2 | 2020-04-23 | 2021-03-17 | |
| Long-term Follow-up Study of Patients Receiving CAR-T Cells Long-Term Follow-Up of Participants who Received CAR-T cells - Chronic Lymphocytic Leukemia, Lymphomas Non-Hodgkin's B-Cell | Recruiting | Medical College of Wisconsin | 500 | 2017-12-01 | 2025-11-10 | |
| Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) JCAR017 (lisocabtagene maraleucel), JCAR017 (lisocabtagene maraleucel) + ibrutinib, JCAR017 (lisocabtagene maraleucel) + venetoclax - Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Small Lymphocytic | Phase 1 / Phase 2 | Active not recruiting | Juno Therapeutics, a Subsidiary of Celgene | 320 | 2017-11-27 | 2026-07-06 |
| Efficacy and Safety of Ibrutinib in Patients With CLL and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers Ibrutinib - Chronic Lymphocytic Leukemia, Indolent B-cell Lymphomas | Phase 3 | Unknown | The University of Hong Kong | 62 | 2016-11-01 | 2018-04-12 |
| Multicenter Study of Pacritinib Combined With Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Pacritinib, Ibrutinib - Chronic Lymphocytic Leukemia, Lymphoma, Small Lymphocytic | Phase 1 / Phase 2 | Withdrawn | University of Michigan Rogel Cancer Center | 2016-10-01 | 2017-09-06 | |
| Duvelisib With Obinutuzumab in Patients With CLL/SLL Previously Treated With a BTKi (SYNCHRONY) IPI-145 (duvelisib), Obinutuzumab - Lymphocytic Leukemia, Chronic, Lymphoma, Small Lymphocytic | Phase 1 | Terminated | SecuraBio | 3 | 2015-02-01 | 2023-02-27 |
| Tandem Auto-Allo Transplant for Lymphoma Busulfan (conditioning for AUTO transplant), Etoposide (conditioning for AUTO transplant), Cyclophosphamide (conditioning for AUTO transplant) - Diffuse, Large B-Cell, Lymphoma, Lymphoma, Low-Grade | Phase 2 | Completed | Massachusetts General Hospital | 42 | 2010-08-01 | 2017-03-09 |
| A Phase I Trial Using Cyclophosphamide, Rituximab and Revlimid (CR2) for the Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Small Lymphocytic Lymphoma (SLL) Lenalidomide, Rituximab, and Cyclophosphamide - Leukemia, Lymphocytic, Chronic, B-Cell, Chronic Lymphocytic Leukemia | Phase 1 | Terminated | Emory University | 6 | 2010-07-01 | 2014-08-13 |
| Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas Lenalidomide, Dexamethasone, Rituximab - Follicular Lymphoma, Marginal Zone B-Cell Lymphoma | Phase 2 | Completed | Abramson Cancer Center at Penn Medicine | 50 | 2008-07-01 | 2023-03-30 |
| EL625 in Persistent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma cenersen sodium, Rituximab, Cyclophosphamide - Lymphoma, Small Lymphocytic, Leukemia, Lymphocytic, Chronic | Phase 2 | Terminated | David Rizzieri | 20 | 2008-02-01 | 2012-11-28 |
| Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL veltuzumab - NHL, Lymphoma, Non-Hodgkin | Phase 1 / Phase 2 | Completed | Gilead Sciences | 32 | 2008-01-01 | 2021-08-16 |
| Rituximab Plus Beta-Glucan in Chronic Lymphocytic Leukemia(CLL)/Small Lymphocytic Lymphoma (SLL) Rituximab, Beta-Glucan - Leukemia, Lymphocytic, Chronic, Lymphoma, Small Lymphocytic | Phase 2 | Terminated | University of Louisville | 2 | 2006-03-01 | 2018-05-04 |
| Fludarabine, Rituximab, and Alemtuzumab for B-Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Fludarabine, Rituximab, Alemtuzumab - Lymphoma, Small Lymphocytic, Lymphocytic Leukemia, Chronic | Phase 2 | Completed | Ohio State University Comprehensive Cancer Center | 8 | 2005-08-01 | 2017-02-08 |
| A Pilot Study of Pivanex in Patients With Chronic Lymphocytic Leukemia Pivanex - Leukemia, Lymphocytic, Chronic, Lymphoma, Small Lymphocytic | Phase 2 | Terminated | Titan Pharmaceuticals | 28 | 2004-05-01 | 2005-08-30 |
| Dose Ranging Trial for Pixantrone in the FND-R Variant Regimen in Indolent Non-Hodgkin's Lymphoma Pixantrone (BBR 2778), fludarabine, dexamethasone - Lymphoma, Low-Grade, Lymphoma, Small Lymphocytic | Phase 1 | Completed | CTI BioPharma | 30 | 2001-12-01 | 2015-01-19 |
| A Safety and Effectiveness Study of Vaccine Therapy in Patients With Indolent Lymphoma autologous human tumor-derived HSPPC-96 - Lymphoma, Follicular, Lymphoma, Small Lymphocytic | Phase 2 | Completed | Agenus Inc. | 35 | 2000-03-01 | 2023-09-28 |
Leukemia, Lymphocytic, Chronic, B-Cell (19) · Lymphoma, Follicular (7) · Lymphoma, Non-Hodgkin (5) · Lymphoma, Mantle-Cell (4) · Lymphoma (3) · Waldenstrom Macroglobulinemia (3) · Leukemia (2) · Lymphoma, B-Cell (2) · Lymphoma, B-Cell, Marginal Zone (2) · Lymphoma, Large B-Cell, Diffuse (2) · Burkitt Lymphoma (1) · Dendritic Cell Sarcoma, Interdigitating (1) · Feeding Behavior (1) · Hepatitis B, Chronic (1) · Hereditary Sensory and Autonomic Neuropathies (1)
Chronic Disease (19) · Disease Attributes (19) · Hematologic Diseases (19) · Hemic and Lymphatic Diseases (19) · Immune System Diseases (19) · Immunoproliferative Disorders (19) · Leukemia, Lymphoid (19) · Lymphatic Diseases (19) · Lymphoproliferative Disorders (19) · Neoplasms by Histologic Type (19) · Pathologic Processes (19) · Pathological Conditions, Signs and Symptoms (19) · Leukemia, B-Cell (18) · Neoplasms (18) · Leukemia (17)
Rituximab (7) · fludarabine (4) · Cyclophosphamide (3) · fludarabine phosphate (3) · ibrutinib (3) · Dexamethasone (2) · Lenalidomide (2) · duvelisib (2) · venetoclax (2) · 11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (1) · ARQ531 (1) · Alemtuzumab (1) · Busulfan (1) · Calcium Dobesilate (1) · Etoposide (1)
SecuraBio (2) · Abramson Cancer Center at Penn Medicine (1) · Agenus Inc. (1) · CTI BioPharma (1) · David Rizzieri (1) · Eleah Stringer (1) · Eli Lilly and Company (1) · Emory University (1) · Gilead Sciences (1) · Juno Therapeutics, a Subsidiary of Celgene (1) · Massachusetts General Hospital (1) · Medical College of Wisconsin (1) · Merck Sharp & Dohme LLC (1) · Ohio State University Comprehensive Cancer Center (1) · The University of Hong Kong (1)
United States (17) · Canada (5) · Australia (2) · Belgium (2) · France (2) · Israel (2) · Italy (2) · Japan (2) · Spain (2) · United Kingdom (2) · Argentina (1) · Austria (1) · Brazil (1) · Chile (1) · China (1)
David Rizzieri, MD (1) · John C. Byrd, M.D. (1) · Nirav Shah (1) · Rajni Sinha, MD (1) · Roger H Herzig, MD (1) · Ryan Wilcox, M.D. (1) · Scott Stromatt, MD (1) · Stephen J Schuster, MD (1) · William Wegener, MD, PhD (1) · Yi-Bin A Chen, MD (1) · Yok Lam Kwong, MD(HK), (1)
PMID 21173095, PMID 21681734, PMID 26009261, PMID 26389849, PMID 34699592, PMID 35610089, PMID 37295445, PMID 42520199